2021 Q4 Form 10-K Financial Statement
#000143774922006778 Filed on March 21, 2022
Income Statement
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| Revenue | $16.17M | $48.04M | $7.970M |
| YoY Change | 102.94% | 307.17% | |
| Cost Of Revenue | $1.589M | $5.157M | $650.0K |
| YoY Change | 144.46% | 411.1% | |
| Gross Profit | $14.59M | $42.89M | $7.310M |
| YoY Change | 99.52% | 297.45% | |
| Gross Profit Margin | 90.18% | 89.27% | 91.72% |
| Selling, General & Admin | $21.42M | $87.54M | $22.16M |
| YoY Change | -3.35% | -2.97% | 12.2% |
| % of Gross Profit | 146.85% | 204.12% | 303.15% |
| Research & Development | $13.08M | $47.64M | $12.41M |
| YoY Change | 5.41% | 0.7% | -38.23% |
| % of Gross Profit | 89.69% | 111.09% | 169.77% |
| Depreciation & Amortization | $213.0K | $800.0K | $120.0K |
| YoY Change | 77.5% | 100.0% | 9.09% |
| % of Gross Profit | 1.46% | 1.87% | 1.64% |
| Operating Expenses | $34.50M | $135.2M | $34.57M |
| YoY Change | -0.2% | -1.71% | -13.23% |
| Operating Profit | -$19.92M | -$92.29M | -$27.26M |
| YoY Change | -26.94% | -27.18% | -31.57% |
| Interest Expense | $20.00K | $365.0K | $270.0K |
| YoY Change | -92.59% | -81.66% | -73.27% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$7.420M | -$17.44M | -$170.0K |
| YoY Change | 4264.71% | 4745.56% | 21.43% |
| Pretax Income | -$27.32M | -$109.4M | -$27.15M |
| YoY Change | 0.61% | -12.58% | -30.33% |
| Income Tax | $1.137M | $1.449M | $3.370M |
| % Of Pretax Income | |||
| Net Earnings | -$28.45M | -$110.8M | -$30.53M |
| YoY Change | -6.81% | -13.75% | -21.66% |
| Net Earnings / Revenue | -175.91% | -230.67% | -383.06% |
| Basic Earnings Per Share | -$4.96 | ||
| Diluted Earnings Per Share | -$1.268M | -$4.959M | -$1.378M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 22.42M | 22.35M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $89.14M | $89.14M | $102.0M |
| YoY Change | -12.62% | -12.61% | -30.64% |
| Cash & Equivalents | $44.36M | $44.36M | $52.86M |
| Short-Term Investments | $44.78M | $44.78M | $49.15M |
| Other Short-Term Assets | $8.702M | $8.702M | $4.600M |
| YoY Change | 89.17% | 89.17% | 206.67% |
| Inventory | $4.832M | $4.832M | $1.964M |
| Prepaid Expenses | |||
| Receivables | $11.72M | $11.72M | $7.047M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $114.4M | $114.4M | $115.6M |
| YoY Change | -1.06% | -1.05% | -22.21% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $1.967M | $3.147M | $2.046M |
| YoY Change | -3.86% | -25.07% | 109.42% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $675.0K | $675.0K | $1.900M |
| YoY Change | -64.47% | -64.47% | -96.09% |
| Other Assets | $1.311M | $1.534M | $66.00K |
| YoY Change | 1886.36% | 411.33% | -75.0% |
| Total Long-Term Assets | $5.356M | $5.356M | $6.386M |
| YoY Change | -16.13% | -16.31% | -88.12% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $114.4M | $114.4M | $115.6M |
| Total Long-Term Assets | $5.356M | $5.356M | $6.386M |
| Total Assets | $119.7M | $119.7M | $122.0M |
| YoY Change | -1.85% | -1.85% | -39.72% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $5.786M | $5.786M | $3.271M |
| YoY Change | 76.89% | 75.33% | -30.32% |
| Accrued Expenses | $14.35M | $14.35M | $17.50M |
| YoY Change | -17.98% | -17.98% | 18.24% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $22.38M | $22.38M | $21.44M |
| YoY Change | 4.4% | 4.58% | 10.03% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $88.95M | $88.95M | $4.200M |
| YoY Change | 2017.93% | 2017.93% | 61.54% |
| Total Long-Term Liabilities | $0.00 | $88.95M | $4.200M |
| YoY Change | -100.0% | 2017.93% | 61.54% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $22.38M | $22.38M | $21.44M |
| Total Long-Term Liabilities | $0.00 | $88.95M | $4.200M |
| Total Liabilities | $111.3M | $111.3M | $25.65M |
| YoY Change | 334.05% | 333.2% | 16.14% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$467.3M | -$356.5M | |
| YoY Change | 31.08% | 56.36% | |
| Common Stock | $475.8M | $452.6M | |
| YoY Change | 5.12% | 10.92% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $8.413M | $8.413M | $96.36M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $119.7M | $119.7M | $122.0M |
| YoY Change | -1.85% | -1.85% | -39.72% |
Cashflow Statement
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$28.45M | -$110.8M | -$30.53M |
| YoY Change | -6.81% | -13.75% | -21.66% |
| Depreciation, Depletion And Amortization | $213.0K | $800.0K | $120.0K |
| YoY Change | 77.5% | 100.0% | 9.09% |
| Cash From Operating Activities | -$20.07M | -$84.89M | -$21.25M |
| YoY Change | -5.55% | -19.83% | -18.27% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$202.0K | $752.0K | -$180.0K |
| YoY Change | 12.22% | -38.11% | -10.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $9.327M | $4.821M | $49.63M |
| YoY Change | -81.21% | -94.9% | 422.97% |
| Cash From Investing Activities | $9.125M | $4.069M | $49.47M |
| YoY Change | -81.55% | -95.64% | 431.94% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | ||
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -32.00K | $72.32M | 80.00K |
| YoY Change | -140.0% | 337.58% | -66.67% |
| NET CHANGE | |||
| Cash From Operating Activities | -20.07M | -$84.89M | -21.25M |
| Cash From Investing Activities | 9.125M | $4.069M | 49.47M |
| Cash From Financing Activities | -32.00K | $72.32M | 80.00K |
| Net Change In Cash | -10.98M | -$8.504M | 28.30M |
| YoY Change | -138.79% | -319.23% | -271.93% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$20.07M | -$84.89M | -$21.25M |
| Capital Expenditures | -$202.0K | $752.0K | -$180.0K |
| Free Cash Flow | -$19.87M | -$85.64M | -$21.07M |
| YoY Change | -5.7% | -20.03% | -18.33% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
942000 | USD |
| CY2021 | dei |
Auditor Location
AuditorLocation
|
Florham Park, New Jersey | |
| CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22462995 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22462995 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22167791 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22167791 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
90520000 | USD |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
271000 | USD |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
USD | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
90791000 | USD |
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y5M15D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y3M3D | |
| CY2020Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
|
235000 | USD |
| CY2020Q4 | urgn |
Lessor Operating Lease Payment To Be Received After Year Four
LessorOperatingLeasePaymentToBeReceivedAfterYearFour
|
USD | |
| CY2020Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
|
778000 | USD |
| CY2019Q4 | urgn |
Accrued Sales Reserve
AccruedSalesReserve
|
0 | USD |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000.0 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22500000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22200000 | |
| CY2021 | urgn |
Maximum Term For Commitment To Continue Employment Of Research And Development Jobs
MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs
|
P3Y | |
| CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
44360000 | USD |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
52864000 | USD |
| CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
44779000 | USD |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
49154000 | USD |
| CY2021Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1226000 | USD |
| CY2020Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1226000 | USD |
| CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
11717000 | USD |
| CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
7047000 | USD |
| CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
4832000 | USD |
| CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
1964000 | USD |
| CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
7476000 | USD |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3364000 | USD |
| CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
114390000 | USD |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
115619000 | USD |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1967000 | USD |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2046000 | USD |
| CY2021Q4 | us-gaap |
Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
|
223000 | USD |
| CY2020Q4 | us-gaap |
Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
|
223000 | USD |
| CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1180000 | USD |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2158000 | USD |
| CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
675000 | USD |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
1893000 | USD |
| CY2021Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1311000 | USD |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
66000 | USD |
| CY2021Q4 | us-gaap |
Assets
Assets
|
119746000 | USD |
| CY2020Q4 | us-gaap |
Assets
Assets
|
122005000 | USD |
| CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
12102000 | USD |
| CY2020Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
10023000 | USD |
| CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6948000 | USD |
| CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
9554000 | USD |
| CY2021Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3330000 | USD |
| CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1859000 | USD |
| CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
22380000 | USD |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
21436000 | USD |
| CY2021Q4 | urgn |
Prepaid Forward Obligation
PrepaidForwardObligation
|
85713000 | USD |
| CY2020Q4 | urgn |
Prepaid Forward Obligation
PrepaidForwardObligation
|
0 | USD |
| CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
398000 | USD |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1497000 | USD |
| CY2021Q4 | us-gaap |
Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
|
2842000 | USD |
| CY2020Q4 | us-gaap |
Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
|
2717000 | USD |
| CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
111333000 | USD |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
25650000 | USD |
| CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
61000 | USD |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
60000 | USD |
| CY2021Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
475698000 | USD |
| CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
452525000 | USD |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-467321000 | USD |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-356501000 | USD |
| CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-25000 | USD |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
271000 | USD |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8413000 | USD |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
96355000 | USD |
| CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
119746000 | USD |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
122005000 | USD |
| CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
48042000 | USD |
| CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
11799000 | USD |
| CY2021 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
5157000 | USD |
| CY2020 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
1009000 | USD |
| CY2021 | us-gaap |
Gross Profit
GrossProfit
|
42885000 | USD |
| CY2020 | us-gaap |
Gross Profit
GrossProfit
|
10790000 | USD |
| CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
47642000 | USD |
| CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
47310000 | USD |
| CY2021 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
87535000 | USD |
| CY2020 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
90219000 | USD |
| CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-92292000 | USD |
| CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-126739000 | USD |
| CY2021 | urgn |
Financing On Prepaid Forward Obligation
FinancingOnPrepaidForwardObligation
|
17291000 | USD |
| CY2020 | urgn |
Financing On Prepaid Forward Obligation
FinancingOnPrepaidForwardObligation
|
-0 | USD |
| CY2021 | urgn |
Interest And Other Income Net
InterestAndOtherIncomeNet
|
212000 | USD |
| CY2020 | urgn |
Interest And Other Income Net
InterestAndOtherIncomeNet
|
1629000 | USD |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-109371000 | USD |
| CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-125110000 | USD |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1449000 | USD |
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
3374000 | USD |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-110820000 | USD |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-128484000 | USD |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-110820000 | USD |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-128484000 | USD |
| CY2021 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-296000 | USD |
| CY2020 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-5000 | USD |
| CY2021 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-111116000 | USD |
| CY2020 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-128489000 | USD |
| CY2021 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-4.96 | |
| CY2020 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-5.90 | |
| CY2021 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22347481 | |
| CY2020 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
21780826 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
180302000 | USD |
| CY2020 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
740000 | USD |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
28025000 | USD |
| CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
15777000 | USD |
| CY2020 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-5000 | USD |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-128484000 | USD |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
96355000 | USD |
| CY2021 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
61000 | USD |
| CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
23113000 | USD |
| CY2021 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-296000 | USD |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-110820000 | USD |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8413000 | USD |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-110820000 | USD |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-128484000 | USD |
| CY2021 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
831000 | USD |
| CY2020 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
416000 | USD |
| CY2021 | urgn |
Accrued Financing On Prepaid Forward Obligation
AccruedFinancingOnPrepaidForwardObligation
|
14848000 | USD |
| CY2020 | urgn |
Accrued Financing On Prepaid Forward Obligation
AccruedFinancingOnPrepaidForwardObligation
|
0 | USD |
| CY2021 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-476000 | USD |
| CY2020 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-439000 | USD |
| CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
23113000 | USD |
| CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
28025000 | USD |
| CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
4069000 | USD |
| CY2020 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
1628000 | USD |
| CY2021 | urgn |
Operating Lease Liability Noncash Adjustments
OperatingLeaseLiabilityNoncashAdjustments
|
1176000 | USD |
| CY2020 | urgn |
Operating Lease Liability Noncash Adjustments
OperatingLeaseLiabilityNoncashAdjustments
|
1541000 | USD |
| CY2021 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2868000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1964000 | USD |
| CY2021 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4671000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
7047000 | USD |
| CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4111000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2330000 | USD |
| CY2021 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
1020000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-0 | USD |
| CY2021 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1998000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1245000 | USD |
| CY2021 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-2606000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
2843000 | USD |
| CY2021 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
47000 | USD |
| CY2020 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
657000 | USD |
| CY2021 | urgn |
Increase Decrease In Uncertain Tax Positions
IncreaseDecreaseInUncertainTaxPositions
|
125000 | USD |
| CY2020 | urgn |
Increase Decrease In Uncertain Tax Positions
IncreaseDecreaseInUncertainTaxPositions
|
2717000 | USD |
| CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-84892000 | USD |
| CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-105886000 | USD |
| CY2021 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
51898000 | USD |
| CY2020 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
29688000 | USD |
| CY2021 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
2463000 | USD |
| CY2020 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
0 | USD |
| CY2021 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
54256000 | USD |
| CY2020 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
124141000 | USD |
| CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
752000 | USD |
| CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1215000 | USD |
| CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
93238000 | USD |
| CY2021 | urgn |
Proceeds From Prepaid Forward Arrangement Net
ProceedsFromPrepaidForwardArrangementNet
|
72402000 | USD |
| CY2020 | urgn |
Proceeds From Prepaid Forward Arrangement Net
ProceedsFromPrepaidForwardArrangementNet
|
0 | USD |
| CY2021 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
61000 | USD |
| CY2020 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
740000 | USD |
| CY2021 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
| CY2020 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
15853000 | USD |
| CY2021 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
144000 | USD |
| CY2020 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
66000 | USD |
| CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
72319000 | USD |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
16527000 | USD |
| CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-8504000 | USD |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
3879000 | USD |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
54090000 | USD |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
50211000 | USD |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
45586000 | USD |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
54090000 | USD |
| CY2021 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | USD |
| CY2020 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
270000 | USD |
| CY2021 | urgn |
Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
81000 | USD |
| CY2020 | urgn |
Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
0 | USD |
| CY2021 | urgn |
Non Cash New Lease Liabilities
NonCashNewLeaseLiabilities
|
-36000 | USD |
| CY2020 | urgn |
Non Cash New Lease Liabilities
NonCashNewLeaseLiabilities
|
51000 | USD |
| CY2021 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a href="#" id="notes" title="notes"/>Note <em style="font: inherit;">1</em>-Business and Nature of Operations</b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> clinical development of UGN-<em style="font: inherit;">102,</em> and raising capital to support and expand these activities.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> | |
| CY2021 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">N<b>ote</b><i> </i><b><em style="font: inherit;">2</em></b><i> </i>– <b>Basis of Presentation</b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-size: 10pt; margin: 0pt; font-family: Calibri;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.</p> <p style="font-size: 10pt; margin: 0pt; font-family: Calibri;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit of $467.3 million and $356.5 million as of <em style="font: inherit;"> December 31, 2021</em> and <em style="font: inherit;">2020</em>, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it expands its portfolio and engages in further research and development activities, particularly conducting nonclinical studies and clinical trials.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities, in addition to our recently announced debt financing agreement (see Note <em style="font: inherit;">19</em> for additional details) are sufficient to fund the Company’s planned operations for at least the next <em style="font: inherit;">12</em> months. <span style="font-size: 10pt; font-family: Calibri;"><span style="background-color:#ffffff;">The Company anticipates that it will need to raise additional capital in the future</span></span>. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p> | |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-467300000 | USD |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-356500000 | USD |
| CY2021 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"/> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to these consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p> | |
| CY2021 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"/><p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"/> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p> | |
| CY2021 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-4.96 | |
| CY2020 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-5.90 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-110820000 | USD |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-128484000 | USD |
| CY2021 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22347481 | |
| CY2020 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
21780826 | |
| CY2021 | urgn |
Other Finance Income Expense
OtherFinanceIncomeExpense
|
-153000 | USD |
| CY2020 | urgn |
Other Finance Income Expense
OtherFinanceIncomeExpense
|
-357000 | USD |
| CY2021 | urgn |
Interest And Other Income Net
InterestAndOtherIncomeNet
|
212000 | USD |
| CY2020 | urgn |
Interest And Other Income Net
InterestAndOtherIncomeNet
|
1629000 | USD |
| CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5786000 | USD |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3271000 | USD |
| CY2021Q4 | urgn |
Accrued Sales Reserve Current
AccruedSalesReserveCurrent
|
497000 | USD |
| CY2020Q4 | urgn |
Accrued Sales Reserve Current
AccruedSalesReserveCurrent
|
382000 | USD |
| CY2021Q4 | urgn |
Accrued Clinical Expense
AccruedClinicalExpense
|
1377000 | USD |
| CY2020Q4 | urgn |
Accrued Clinical Expense
AccruedClinicalExpense
|
1359000 | USD |
| CY2021Q4 | urgn |
Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
|
1748000 | USD |
| CY2020Q4 | urgn |
Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
|
1356000 | USD |
| CY2021Q4 | urgn |
Accrued Selling General And Administrative Expense
AccruedSellingGeneralAndAdministrativeExpense
|
1965000 | USD |
| CY2020Q4 | urgn |
Accrued Selling General And Administrative Expense
AccruedSellingGeneralAndAdministrativeExpense
|
2440000 | USD |
| CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
729000 | USD |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1215000 | USD |
| CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
12102000 | USD |
| CY2020Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
10023000 | USD |
| CY2021 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
365000 | USD |
| CY2020 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1986000 | USD |
| CY2021Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
3894000 | USD |
| CY2020Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
1051000 | USD |
| CY2021Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1958000 | USD |
| CY2020Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
913000 | USD |
| CY2021Q4 | urgn |
Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
|
5852000 | USD |
| CY2020Q4 | urgn |
Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
|
1964000 | USD |
| CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
26000 | USD |
| CY2021Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
66882000 | USD |
| CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | USD |
| CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
66856000 | USD |
| CY2021Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
|
26000 | USD |
| CY2021Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
37000000.0 | USD |
| CY2021Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
|
23 | pure |
| CY2021Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
66181000 | USD |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
88898000 | USD |
| CY2021Q4 | urgn |
Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three
DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
|
675000 | USD |
| CY2020Q4 | urgn |
Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three
DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
|
1893000 | USD |
| CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
66856000 | USD |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
90791000 | USD |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
4193000 | USD |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3441000 | USD |
| CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2226000 | USD |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1395000 | USD |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1967000 | USD |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2046000 | USD |
| CY2021 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
800000 | USD |
| CY2020 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
400000 | USD |
| CY2021Q2 | urgn |
Prepaid Forward Obligation
PrepaidForwardObligation
|
75000000 | USD |
| urgn |
Capitalized Closing Costs On Prepaid Forward Obligation
CapitalizedClosingCostsOnPrepaidForwardObligation
|
2599000 | USD | |
| urgn |
Financing On Prepaid Forward Obligation
FinancingOnPrepaidForwardObligation
|
17291000 | USD | |
| urgn |
Decrease In Prepaid Forward Obligation Amounts Paid And Payable
DecreaseInPrepaidForwardObligationAmountsPaidAndPayable
|
3979000 | USD | |
| CY2021Q4 | urgn |
Prepaid Forward Obligation
PrepaidForwardObligation
|
85713000 | USD |
| CY2020Q4 | us-gaap |
Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
|
200000 | USD |
| CY2021 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1045000 | USD |
| CY2020 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1812000 | USD |
| CY2021 | us-gaap |
Sublease Income
SubleaseIncome
|
224000 | USD |
| CY2020 | us-gaap |
Sublease Income
SubleaseIncome
|
224000 | USD |
| CY2021 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
66000 | USD |
| CY2020 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
129000 | USD |
| CY2021 | us-gaap |
Lease Cost
LeaseCost
|
887000 | USD |
| CY2020 | us-gaap |
Lease Cost
LeaseCost
|
1717000 | USD |
| CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1180000 | USD |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2158000 | USD |
| CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
398000 | USD |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1497000 | USD |
| CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
3026000 | USD |
| CY2020 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1726000 | USD |
| CY2021 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
135000 | USD |
| CY2020 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
135000 | USD |
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0562 | pure |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0538 | pure |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1141000 | USD |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
357000 | USD |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
58000 | USD |
| CY2021Q4 | urgn |
Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
|
0 | USD |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1556000 | USD |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
69000 | USD |
| CY2021Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1487000 | USD |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1307000 | USD |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1150000 | USD |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
357000 | USD |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
58000 | USD |
| CY2020Q4 | urgn |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
0 | USD |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
2872000 | USD |
| CY2021Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
|
243000 | USD |
| CY2021Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
|
251000 | USD |
| CY2021Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
|
49000 | USD |
| CY2021Q4 | urgn |
Lessor Operating Lease Payment To Be Received After Year Three
LessorOperatingLeasePaymentToBeReceivedAfterYearThree
|
0 | USD |
| CY2021Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
|
543000 | USD |
| CY2020Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
|
243000 | USD |
| CY2020Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
|
251000 | USD |
| CY2020Q4 | us-gaap |
Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
|
49000 | USD |
| CY2021 | us-gaap |
Sublease Income
SubleaseIncome
|
224000 | USD |
| CY2020 | us-gaap |
Sublease Income
SubleaseIncome
|
224000 | USD |
| CY2020 | urgn |
Sales Reserve Accruals
SalesReserveAccruals
|
2694000 | USD |
| CY2020 | urgn |
Sales Reserve Utilization
SalesReserveUtilization
|
-1852000 | USD |
| CY2020Q4 | urgn |
Accrued Sales Reserve
AccruedSalesReserve
|
842000 | USD |
| CY2021 | urgn |
Sales Reserve Accruals
SalesReserveAccruals
|
8239000 | USD |
| CY2021 | urgn |
Sales Reserve Utilization
SalesReserveUtilization
|
-7373000 | USD |
| CY2021Q4 | urgn |
Accrued Sales Reserve
AccruedSalesReserve
|
1708000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
1207000 | USD |
| CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000.0 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22500000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22200000 | |
| CY2021Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
3722831 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1168949 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
593000 | |
| CY2021 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
11.92 | |
| CY2021 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
22.07 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
400600 | |
| CY2020 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
16.50 | |
| CY2020 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
29.41 | |
| CY2021 | urgn |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedFairValue
|
7000000.0 | USD |
| CY2020 | urgn |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedFairValue
|
6700000 | USD |
| CY2021Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
7300000 | USD |
| CY2021 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y11M1D | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
200000 | USD |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2300000 | USD |
| CY2021 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
23656000 | USD |
| CY2020 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
26370000 | USD |
| CY2021 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
617000 | USD |
| CY2020 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
105000 | USD |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1449000 | USD |
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
3374000 | USD |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-10100000 | USD |
| CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-17000000.0 | USD |
| CY2021Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
335800000 | USD |
| CY2020Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
250200000 | USD |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2717000 | USD |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | USD |
| CY2021 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
0 | USD |
| CY2020 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
2717000 | USD |
| CY2021 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
125000 | USD |
| CY2020 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
0 | USD |
| CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2842000 | USD |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2717000 | USD |
| CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2800000 | USD |
| CY2021Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
2969557 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
2149699 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
2400000 | USD |
| CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
23113000 | USD |
| CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
28025000 | USD |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.23 | pure |
| CY2021 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
1454000 | USD |
| CY2020 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
3218000 | USD |
| CY2021 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
-5000 | USD |
| CY2020 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
156000 | USD |
| CY2021 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
1449000 | USD |
| CY2020 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
3374000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
77277000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
57607000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
8988000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
5362000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
9278000 | USD |
| CY2021Q4 | urgn |
Deferred Tax Assets Issuance Costs
DeferredTaxAssetsIssuanceCosts
|
65000 | USD |
| CY2020Q4 | urgn |
Deferred Tax Assets Issuance Costs
DeferredTaxAssetsIssuanceCosts
|
978000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
1909000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
1589000 | USD |
| CY2021Q4 | urgn |
Deferred Tax Assets Depreciation Of Fixed Assets
DeferredTaxAssetsDepreciationOfFixedAssets
|
-158000 | USD |
| CY2020Q4 | urgn |
Deferred Tax Assets Depreciation Of Fixed Assets
DeferredTaxAssetsDepreciationOfFixedAssets
|
-299000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
2329000 | USD |
| CY2021Q4 | urgn |
Deferred Tax Assets Rightofuse Asset
DeferredTaxAssetsRightofuseAsset
|
-228000 | USD |
| CY2020Q4 | urgn |
Deferred Tax Assets Rightofuse Asset
DeferredTaxAssetsRightofuseAsset
|
-372000 | USD |
| CY2021Q4 | urgn |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
282000 | USD |
| CY2020Q4 | urgn |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
473000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
10958000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
319000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
18000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
100619000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
76963000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
76963000 | USD |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
50593000 | USD |
| CY2021 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
23656000 | USD |
| CY2020 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
26370000 | USD |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
100619000 | USD |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
76963000 | USD |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-109371000 | USD |
| CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-125110000 | USD |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.23 | pure |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.23 | pure |
| CY2021 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-25155000 | USD |
| CY2020 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-28775000 | USD |
| CY2021 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
2264000 | USD |
| CY2020 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
2940000 | USD |
| CY2021 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-58000 | USD |
| CY2020 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
17000 | USD |
| CY2021 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
125000 | USD |
| CY2020 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
2717000 | USD |
| CY2021Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
900000 | USD |
| CY2020Q1 | us-gaap |
Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
|
6600000 | USD |
| CY2021 | urgn |
Maximum Percentage Of Commitment To Continue Employment Of Research And Development Jobs
MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs
|
0.75 | pure |
